PHILADELPHIA —While more women die from heart disease each year than all forms of cancer combined, many are more fearful of other diseases, particularly breast cancer. This phenomenon, referred to as “misfearing,” describes the human tendency to fear instinctively and according to societal influences rather than based on facts. This trend may be a contributor to the reasons why many women fail to take enough steps -- such as changing diet and fitness habits or risk-taking behaviors -- to guard against heart disease.
In a Perspective column today in the New England Journal of Medicine, Penn Medicine cardiologist and Robert Wood Johnson Foundation Clinical Scholar Lisa Rosenbaum, MD, notes that although the first decade of educational campaigns to inform women about heart disease “led to a near doubling of women’s knowledge about heart disease, in the past few years, such efforts have failed to reap further gains.” Moreover, “persistent gaps in perceptions remain among minority women, who are often at greatest risk.”
Simply reinforcing the facts about the prevalence and potential prevention of heart disease among women is likely not enough to improve on these results, says Rosenbaum. Instead, physicians and others in health care need to develop an understanding of the misfearing paradigm and how “social values” and “group identities” affect patients’ perceptions of disease.
“The big, the dramatic, and the memorable occupy far more of our worry budget than the things that kill with far greater frequency: strokes, diabetes, heart disease,” she writes. “But interacting with many of these fear factors is another force we rarely associate with our individual health perceptions: our commitment to our cultural groups.”
Women’s focus on breast cancer may be tied, according to Rosenbaum, to “intuitions about female identity” that shape their interpretation of health-related information and relevant behavior. Because breast cancer “attacks a body part that is so fundamental to female identity,” she asks if “to be a woman, one must join the war on this disease,” and consequently focus less on heart disease (which is often linked to such perceived anti-feminine contributing factors as cigarettes and obesity). Additionally, Rosenbaum asks, “Are we held up by our ideal of beauty? We can each summon the images of beautiful young women with breast cancer. Where are all the beautiful women with heart disease?”
While acknowledging the very real threat of women’s cancers, Dr. Rosenbaum advocates physicians taking a different approach to conversations with female patients about cardiovascular health. To “make it easier for women in our society to feel like women” and yet acknowledge they’re at risk for heart disease, she advocates several steps. These include:
- emphasizing that, like cancer, heart disease can result from bad luck and not simply one’s unappealing habits
- “creating communities of women in which stories about living with heart disease are as celebrated as stories of surviving breast cancer”
- prioritizing the study of how values and group norms affect health perceptions and associated behaviors.
“Whether we’re aware of our group commitments or not, we cannot shed our deeply rooted herd mentality nor change our visceral allegiances to our tribe,” Rosenbaum writes. “Developing an understanding of how such factors inform our perceptions of disease is critical to improving the health of our population. Certainly, understanding of one’s risk for any disease must be anchored in facts. But if we want our facts to translate into better health, we may need to start talking more about our feelings.”
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.